VAN-RIZATRIPTAN ODT TABLET (ORALLY DISINTEGRATING)

国: カナダ

言語: 英語

ソース: Health Canada

有効成分:

RIZATRIPTAN (RIZATRIPTAN BENZOATE)

から入手可能:

VANC PHARMACEUTICALS INC

ATCコード:

N02CC04

INN（国際名）:

RIZATRIPTAN

投薬量:

5MG

医薬品形態:

TABLET (ORALLY DISINTEGRATING)

構図:

RIZATRIPTAN (RIZATRIPTAN BENZOATE) 5MG

投与経路:

ORAL

パッケージ内のユニット:

6

処方タイプ:

Prescription

治療領域:

SELECTIVE SEROTONIN AGONISTS

製品概要:

Active ingredient group (AIG) number: 0137841001; AHFS:

認証ステータス:

CANCELLED PRE MARKET

承認日:

2019-07-31

製品の特徴

PRODUCT MONOGRAPH
PR
VAN-RIZATRIPTAN ODT
Rizatriptan Benzoate Orally Disintegrating Tablets
5 mg and 10 mg Rizatriptan (as Rizatriptan Benzoate)
5-HT
1
Receptor Agonist
MIGRAINE THERAPY
Vanc Pharmaceuticals Inc.
Date of Preparation:
210-2639, Viking way 9 November, 2015
Richmond, BC V6V3B7
www.vancpharm.com
Submission Control No: 188668
_ _
_VAN-Rizatriptan ODT _
_ _
_ _
_ _
_ _
_ _
_ _
_ _
_ _
_ Page 2 of 38_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
............................................................... 3
SUMMARY PRODUCT INFORMATION
.....................................................................................
3
INDICATIONS AND CLINICAL USE
...........................................................................................
3
CONTRAINDICATIONS
................................................................................................................
4
WARNINGS AND PRECAUTIONS
..............................................................................................
4
ADVERSE REACTIONS
..............................................................................................................
12
DRUG INTERACTIONS
...............................................................................................................
18
DOSAGE AND ADMINISTRATION
...........................................................................................
20
OVERDOSAGE
.............................................................................................................................
21
ACTION AND CLINICAL PHARMACOLOGY
.........................................................................
22
STORAGE AND STABILITY
......................................................................................................
25
SPECIAL HANDLING INSTRUCTIONS
....................................................................................
25
DOSAGE FORMS, COMPOSITION AND PACKAGING
.......................................................... 26
PART II: SCIENTIFIC INFORMATION